Apixaban is a direct inhibitor of activated factor X (FXa) and is given orally for the prophylaxis of a range of conditions including the prevention of stroke/systemic embolism in atrial fibrillation.
Edoxaban does not require routine anticoagulant monitoring but measurement would be required in certain clinical situations where the result will alter management, including prior to emergency surgery or when bleeding.
Edoxaban is not to be monitored using routine coagulation testing and has no therapeutic reference range at this present time.
Patients undergoing high risk surgery, levels should ideally be less than 30ng/ml.
Patients undergoing lower risk surgerym levels should ideally be below 50ng/ml.
|Min. Volume:||The volume of blood in coagulation samples must lie within the volume range as indicated be the size of the black fill arrow present on the tubes. Volumes above or below the arrow will result in sample rejection to ensure validity of results.||Turnaround Time:||4 hours||Age of Sample:||Samples will be rejected if received more than 2 hours post venepuncture.||Specimen Requirements:||
||Analysing Laboratory:||Coagulation (JCUH)|